EGFR and lung adenocarcinoma: Inhibition of ANKRD1 led to induction of apoptosis by afatinib or osimertinib in adenocarcinoma cells, providing a critical therapeutic target for resistance to EGFR-TKIs in lung adenocarcinoma.